INVIVYD INC. - COMMON STOCK

Invivyd Announces $20 Million to $25 Million Improvement in Projected 2024 Year-End Cash Position

30 Apr 2024 07:30:00 By Nasdaq GlobeNewswire

Invivyd Receives Healthcare Common Procedure Coding System (HCPCS) Reimbursement Codes from the U.S. Centers for Medicare & Medicaid Services (CMS) Covering PEMGARDA™

15 Apr 2024 07:30:00 By Nasdaq GlobeNewswire

Invivyd Announces CEO Transition

12 Apr 2024 07:30:00 By Nasdaq GlobeNewswire

Invivyd Provides PEMGARDA™ Launch Update and Announces 2024 Net Product Revenue Guidance in the Range of $150 Million to $200 Million

04 Apr 2024 16:01:00 By Nasdaq GlobeNewswire

Invivyd Reports Full Year 2023 Financial Results and Recent Business Highlights

28 Mar 2024 07:00:00 By Nasdaq GlobeNewswire

Invivyd Announces Interim Exploratory Data on VYD222 from Ongoing CANOPY Clinical Trial

22 Mar 2024 15:28:22 By Nasdaq GlobeNewswire

Invivyd Announces FDA Authorization for Emergency Use of PEMGARDA™ (Formerly VYD222) for Pre-exposure Prophylaxis (PrEP) of COVID-19

22 Mar 2024 15:04:58 By Nasdaq GlobeNewswire

Invivyd to Participate at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

05 Feb 2024 16:02:13 By Nasdaq GlobeNewswire

Invivyd Submits Request for Emergency Use Authorization (EUA) to U.S. FDA for VYD222 for the Pre-exposure Prevention of COVID-19 in Immunocompromised Adults and Adolescents

03 Jan 2024 07:00:00 By Nasdaq GlobeNewswire

Invivyd Announces Positive Initial Results from Ongoing CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of COVID-19

18 Dec 2023 07:00:00 By Nasdaq GlobeNewswire

Invivyd Reports Third Quarter 2023 Financial Results and Recent Business Highlights

09 Nov 2023 16:01:00 By Nasdaq GlobeNewswire

Invivyd to Host Conference Call Discussing Third Quarter 2023 Financial Results and Business Highlights

02 Nov 2023 16:01:00 By Nasdaq GlobeNewswire

Invivyd to Participate in Upcoming Investor Conferences

31 Oct 2023 16:01:00 By Nasdaq GlobeNewswire

Invivyd Announces Dosing of First Participant in CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of Symptomatic COVID-19 

11 Sep 2023 07:00:00 By Nasdaq GlobeNewswire

Invivyd to Participate in Upcoming Investor Conferences

06 Sep 2023 07:00:00 By Nasdaq GlobeNewswire

Invivyd Reports Second Quarter 2023 Financial Results and Business Highlights

10 Aug 2023 16:01:00 By Nasdaq GlobeNewswire

Invivyd to Host Conference Call Discussing Second Quarter 2023 Financial Results and Business Highlights

03 Aug 2023 16:01:00 By Nasdaq GlobeNewswire

Invivyd Announces Appointment of Sara Cotter to Board Of Directors

27 Jul 2023 16:01:00 By Nasdaq GlobeNewswire

Invivyd Announces Additional Positive Initial Data from Ongoing Phase 1 Clinical Trial of VYD222, a Monoclonal Antibody Candidate in Development for the Prevention of Symptomatic COVID-19 in Immunocompromised People

17 Jul 2023 07:00:00 By Nasdaq GlobeNewswire

Invivyd Announces General Alignment with FDA on Pathway to Potential EUA for VYD222 and Anticipated Follow-On Monoclonal Antibody Candidates Designed to Prevent COVID-19

26 Jun 2023 07:00:00 By Nasdaq GlobeNewswire